PNC Financial Services Group’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.6K Hold
10,270
– – ﹤0.01% 3620
2026
Q2
$40.1K Buy
10,270
+2,570
+33% +$9.6K ﹤0.01% 3459
2026
Q1
$29.5K Buy
+7,700
New +$30.7K ﹤0.01% 3506

Other funds holding SABS

PNC Financial Services Group's SABS Position: Q3 2026 in Review

PNC Financial Services Group held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 10,270 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3620.

PNC Financial Services Group first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $40.1K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • PNC Financial Services Group held 10,270 shares of SAB Biotherapeutics worth $32.6K as of Q3 2026.
  • PNC Financial Services Group left its SAB Biotherapeutics share count unchanged in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3620 holding.
  • PNC Financial Services Group first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • PNC Financial Services Group's SAB Biotherapeutics position peaked at $40.1K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.